Ovid Therapeutics (NASDAQ: OVID) restores Nasdaq $1.00 bid-price rule compliance

Rhea-AI Filing Summary

Ovid Therapeutics Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. Nasdaq formally notified the company that it now meets Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, and that the compliance matter is closed.

This means Ovid’s common stock, listed on the Nasdaq Stock Market under the symbol OVID, is no longer at risk from this specific deficiency notice, helping preserve its current exchange listing status.

Positive

• Regained Nasdaq compliance: Nasdaq confirmed Ovid now meets Listing Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share, and closed the compliance matter, reducing prior delisting risk tied to this rule.

Negative

• None.

Insights

Equity & Listing Standards Analyst

Ovid restores Nasdaq bid-price compliance, easing prior delisting risk.

Ovid Therapeutics received a formal notice from Nasdaq that it again complies with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq has closed the matter, indicating the prior deficiency is fully resolved.

Maintaining compliance with Nasdaq’s bid-price rule is important because prolonged non-compliance can lead to delisting, which typically reduces liquidity and visibility. The confirmation that the issue is closed removes that specific overhang tied to the minimum bid price requirement.

Future disclosures in company filings may provide additional context on how Ovid navigates ongoing listing requirements and broader capital-market objectives while its common stock continues to trade on the Nasdaq Stock Market under the symbol OVID.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001636651 0001636651 2025-09-11 2025-09-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

OVID THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38085		46-5270895
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
441 Ninth Avenue, 14th Floor New York, New York				10001
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 646-661-7661

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock par value $0.001 per share		OVID		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 11, 2025, Ovid Therapeutics Inc., a Delaware corporation (the “Company”), received a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies maintain a minimum bid price of at least $1.00 per share, and that the matter is now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized

Date: September 16, 2025

OVID THERAPEUTICS INC.
By:		/s/ Jeffrey Rona
		Jeffrey Rona
		Chief Business and Financial Officer

FAQ

What did Ovid Therapeutics Inc. (OVID) announce in this 8-K filing?

Ovid Therapeutics announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq formally notified the company that it now meets the minimum bid price requirement and that the related compliance matter is closed, preserving its current listing under this rule.

What is Nasdaq Listing Rule 5550(a)(2) mentioned for Ovid Therapeutics (OVID)?

Nasdaq Listing Rule 5550(a)(2) requires listed companies on the Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share. Ovid Therapeutics received confirmation that it again satisfies this rule, resolving a prior deficiency related specifically to its bid price.

How does regaining Nasdaq compliance affect Ovid Therapeutics (OVID) stock?

Regaining Nasdaq compliance removes a specific delisting risk related to Ovid’s minimum bid price. Nasdaq’s notice confirms the company currently meets the $1.00 per share requirement, helping support continued trading of its common stock on the Nasdaq Stock Market under symbol OVID.

Is the Nasdaq compliance issue for Ovid Therapeutics (OVID) now fully resolved?

Yes. Nasdaq sent Ovid Therapeutics a formal notification stating the company has regained compliance with Listing Rule 5550(a)(2). The exchange also indicated that the compliance matter is now closed, meaning no ongoing deficiency remains under this particular bid price rule.

Which Ovid Therapeutics executive signed the 8-K about Nasdaq compliance?

The 8-K related to Nasdaq compliance was signed by Jeffrey Rona, Ovid Therapeutics’ Chief Business and Financial Officer. His signature indicates that the company, through an authorized officer, formally acknowledged Nasdaq’s notice confirming renewed compliance with the minimum bid price requirement.